HIV-1 p24 Antibody (24-4): sc-69728

HIV-1 p24 Antibody (24-4) is a mouse monoclonal IgG2b kappa light chain antibody that detects HIV-1 p24 protein of HIV-1 origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). HIV-1 p24 (24-4) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. HIV-1 p24 protein plays a crucial role in the viral life cycle as p24 forms the core of the virus, encapsulating viral RNA and essential enzymes necessary for replication. This structural protein is vital for viral stability and integrity, making p24 a key target for both diagnostic and therapeutic strategies against HIV. By understanding p24 function, researchers can develop more effective treatments and vaccines, as well as improve diagnostic assays for HIV infection. HIV primarily targets critical cells in the human immune system, such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells, leading to the progression of acquired immune deficiency syndrome (AIDS). HIV-1 p24 (24-4) monoclonal antibody′s ability to accurately detect p24 is essential for monitoring viral load and assessing antiretroviral therapy efficacy, thereby contributing to better patient management and outcomes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HIV-1 p24 Antibody (24-4) References:

1. Chimeric synthetic peptides from the nucleocapsid p24 protein of human immunodeficiency virus type-1.  |  Hernández, M., et al. 2001. Biochem Biophys Res Commun. 282: 1-3. PMID: 11263961
2. Full-length sequence analysis of HIV-1 isolate CM237: a CRF01_AE/B intersubtype recombinant from Thailand.  |  Swanson, P., et al. 2003. AIDS Res Hum Retroviruses. 19: 707-12. PMID: 14506784
3. False-positive HIV-1 p24 antigenemia with unusual pattern of neutralization.  |  Barbouche, RM., et al. 1999. Arch Inst Pasteur Tunis. 76: 11-2. PMID: 14666751
4. Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen.  |  Barletta, JM., et al. 2004. Am J Clin Pathol. 122: 20-7. PMID: 15272526
5. [Preparation and characterization of the monoclonal antibody against HIV-1 p24 antigen].  |  Hou, J., et al. 2004. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 20: 699-701. PMID: 15555439
6. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.  |  Lottersberger, J., et al. 2004. Rev Argent Microbiol. 36: 151-7. PMID: 15786866
7. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.  |  Kran, AM., et al. 2005. Vaccine. 23: 4011-5. PMID: 15963359
8. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.  |  Coleman, JK., et al. 2005. AIDS. 19: 1457-66. PMID: 16135898
9. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.  |  Schüpbach, J., et al. 2005. J Acquir Immune Defic Syndr. 40: 250-6. PMID: 16249697
10. Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings.  |  Knuchel, MC., et al. 2006. J Clin Virol. 36: 64-7. PMID: 16431154
11. Cystatin A and HIV-1 p24 antigen expression in tonsillar lymphoid follicles during HIV-1 infection and during highly active antiretroviral therapy.  |  Voltersvik, P., et al. 2006. J Acquir Immune Defic Syndr. 41: 277-84. PMID: 16540928
12. Long-range effects of tag sequence on marginally stabilized structure in HIV-1 p24 capsid protein monitored using NMR.  |  Okazaki, H., et al. 2014. Biochim Biophys Acta. 1844: 1638-47. PMID: 24960591

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HIV-1 p24 Antibody (24-4) has 28 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HIV-1 p24 Antibody (24-4) Specifications

Alternate Product Name: HIV-1 p24

Product Clone Name: 24-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids:

Epitope Target: HIV-1 p24

Epitope Species: HIV-1

Product Reactivity/Detection: Gag p24

Species Reactivity/Detection: HIV-1

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 28 citations in various scientific publications

Available Conjugates/Forms for HIV-1 p24 Antibody (24-4): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin